Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy
- PMID: 19282314
- DOI: 10.1136/hrt.2008.150656
Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy
Abstract
Background: Although the benefit of implantable cardioverter defibrillator (ICD) therapy in patients with hypertrophic cardiomyopathy (HCM) at risk for sudden cardiac arrest is well established, there may be a higher risk for device complications and inappropriate shocks.
Objectives: To determine the incidence of inappropriate ICD shocks and device complications in HCM patients and the impact of young age at ICD implant and atrial fibrillation.
Methods: HCM patients who underwent ICD implantation between January 1988 and December 2005 were included. The frequency of device complications, including pneumothorax, pericardial effusion, haematoma, lead revisions, infection and rate of inappropriate shocks, was determined. ICD shocks were characterised as inappropriate if triggered by sinus tachycardia, atrial fibrillation or device malfunction.
Results: A total of 181 patients were included (mean age 44 (SD 17) years; 62% males). During a mean follow-up of 59 (42) months (4.92 years; 830.75 patient-years), 65 patients (36%) had a total of 88 device complications, including 42 (23%) patients with inappropriate shocks. The rate of inappropriate shocks was 5.3% per year (vs 4% risk of appropriate shocks), and the likelihood of inappropriate ICD shocks per 100 patient-years was 5.1. Younger age and atrial fibrillation were associated with an increased risk of inappropriate ICD discharges.
Conclusions: The rate of inappropriate ICD shocks and frequency of device complications in HCM patients are not insignificant and are most common in younger patients and those with atrial fibrillation. Inappropriate ICD shocks are the most common device complication and should be accounted for when counselling high-risk HCM patients for ICD implantation.
Comment in
-
Implantable defibrillators in hypertrophic cardiomyopathy.Heart. 2009 May;95(9):695-6. doi: 10.1136/hrt.2008.160705. Epub 2009 Mar 11. Heart. 2009. PMID: 19282312 No abstract available.
Similar articles
-
Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.Kardiol Pol. 2005 Oct;63(4):391-7; discussion 398. Kardiol Pol. 2005. PMID: 16273479 English, Polish.
-
Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.J Cardiovasc Electrophysiol. 2010 Aug 1;21(8):883-9. doi: 10.1111/j.1540-8167.2009.01716.x. Epub 2010 Feb 1. J Cardiovasc Electrophysiol. 2010. PMID: 20132378
-
Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.J Am Coll Cardiol. 2008 Nov 18;52(21):1718-23. doi: 10.1016/j.jacc.2008.07.061. J Am Coll Cardiol. 2008. PMID: 19007692
-
Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.J Cardiovasc Electrophysiol. 2008 Oct;19(10):1118-26. doi: 10.1111/j.1540-8167.2008.01147.x. Epub 2008 Mar 31. J Cardiovasc Electrophysiol. 2008. PMID: 18384577 Review.
-
Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications.Circ Arrhythm Electrophysiol. 2013 Jun;6(3):562-8. doi: 10.1161/CIRCEP.113.000392. Epub 2013 May 14. Circ Arrhythm Electrophysiol. 2013. PMID: 23673907 Review.
Cited by
-
Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study.Pediatr Cardiol. 2013 Oct;34(7):1620-7. doi: 10.1007/s00246-013-0676-6. Epub 2013 Mar 20. Pediatr Cardiol. 2013. PMID: 23512332
-
Subcutaneous versus transvenous implantable cardioverter defibrillator in hypertrophic cardiomyopathy: a systematic review and meta-analysis.Cardiovasc Diagn Ther. 2024 Jun 30;14(3):318-327. doi: 10.21037/cdt-24-15. Epub 2024 Jun 27. Cardiovasc Diagn Ther. 2024. PMID: 38975009 Free PMC article.
-
Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy.Front Pharmacol. 2024 Apr 10;15:1379236. doi: 10.3389/fphar.2024.1379236. eCollection 2024. Front Pharmacol. 2024. PMID: 38659580 Free PMC article.
-
Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology-A PROLONG-II Substudy.Sensors (Basel). 2022 Mar 5;22(5):2037. doi: 10.3390/s22052037. Sensors (Basel). 2022. PMID: 35271182 Free PMC article.
-
Cardiac magnetic resonance imaging as a prognostic tool in patients with nonischemic cardiomyopathy.Hosp Pract (1995). 2010 Nov;38(4):75-82. doi: 10.3810/hp.2010.11.343. Hosp Pract (1995). 2010. PMID: 21068530 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical